Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).
1 finding from 1 review
- Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes onlyRR 2.62 [1.85, 3.72]4 studies · 1665 participantsLow